vs
Jack Henry & Associates（JKHY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Jack Henry & Associates的1.2倍（$772.1M vs $619.3M），Jack Henry & Associates净利率更高（20.1% vs 12.7%，领先7.4%），Jack Henry & Associates同比增速更快（7.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $131.4M），过去两年Revvity的营收复合增速更高（9.0% vs 7.2%）
Jack Henry & Associates是1976年成立的美国专业金融科技企业，主要面向社区银行、信用合作社等中小型金融机构提供金融科技及支付处理解决方案，同时帮助区域银行与信用合作社管控风险、完成合规申报，优化升级线上银行业务相关服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
JKHY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$619.3M
营收增速更快
JKHY
高出2.1%
5.9%
净利率更高
JKHY
高出7.4%
12.7%
自由现金流更多
RVTY
多$30.3M
$131.4M
两年增速更快
RVTY
近两年复合增速
7.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $619.3M | $772.1M |
| 净利润 | $124.7M | $98.4M |
| 毛利率 | 43.3% | — |
| 营业利润率 | 25.7% | 14.5% |
| 净利率 | 20.1% | 12.7% |
| 营收同比 | 7.9% | 5.9% |
| 净利润同比 | 27.4% | 3.9% |
| 每股收益（稀释后） | $1.72 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JKHYRVTY
| Q4 25 | $619.3M | $772.1M | ||
| Q3 25 | $644.7M | $698.9M | ||
| Q2 25 | $615.4M | $720.3M | ||
| Q1 25 | $585.1M | $664.8M | ||
| Q4 24 | $573.8M | $729.4M | ||
| Q3 24 | $601.0M | $684.0M | ||
| Q2 24 | $559.9M | $691.7M | ||
| Q1 24 | $538.6M | $649.9M |
净利润JKHYRVTY
| Q4 25 | $124.7M | $98.4M | ||
| Q3 25 | $144.0M | $46.7M | ||
| Q2 25 | $127.6M | $53.9M | ||
| Q1 25 | $111.1M | $42.2M | ||
| Q4 24 | $97.8M | $94.6M | ||
| Q3 24 | $119.2M | $94.4M | ||
| Q2 24 | $101.1M | $55.4M | ||
| Q1 24 | $87.1M | $26.0M |
毛利率JKHYRVTY
| Q4 25 | 43.3% | — | ||
| Q3 25 | 45.9% | 53.6% | ||
| Q2 25 | 44.1% | 54.5% | ||
| Q1 25 | 41.8% | 56.5% | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 42.9% | 56.3% | ||
| Q2 24 | 41.5% | 55.7% | ||
| Q1 24 | 39.1% | 54.6% |
营业利润率JKHYRVTY
| Q4 25 | 25.7% | 14.5% | ||
| Q3 25 | 28.5% | 11.7% | ||
| Q2 25 | 25.3% | 12.6% | ||
| Q1 25 | 23.7% | 10.9% | ||
| Q4 24 | 21.4% | 16.3% | ||
| Q3 24 | 25.2% | 14.3% | ||
| Q2 24 | 22.4% | 12.4% | ||
| Q1 24 | 20.8% | 6.8% |
净利率JKHYRVTY
| Q4 25 | 20.1% | 12.7% | ||
| Q3 25 | 22.3% | 6.7% | ||
| Q2 25 | 20.7% | 7.5% | ||
| Q1 25 | 19.0% | 6.4% | ||
| Q4 24 | 17.1% | 13.0% | ||
| Q3 24 | 19.8% | 13.8% | ||
| Q2 24 | 18.1% | 8.0% | ||
| Q1 24 | 16.2% | 4.0% |
每股收益（稀释后）JKHYRVTY
| Q4 25 | $1.72 | $0.86 | ||
| Q3 25 | $1.97 | $0.40 | ||
| Q2 25 | $1.75 | $0.46 | ||
| Q1 25 | $1.52 | $0.35 | ||
| Q4 24 | $1.34 | $0.77 | ||
| Q3 24 | $1.63 | $0.77 | ||
| Q2 24 | $1.39 | $0.45 | ||
| Q1 24 | $1.19 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.2B | $7.3B |
| 总资产 | $3.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JKHYRVTY
| Q4 25 | $28.2M | $919.9M | ||
| Q3 25 | $36.2M | $931.4M | ||
| Q2 25 | $102.0M | $991.8M | ||
| Q1 25 | $39.9M | $1.1B | ||
| Q4 24 | $25.7M | $1.2B | ||
| Q3 24 | $43.2M | $1.2B | ||
| Q2 24 | $38.3M | $2.0B | ||
| Q1 24 | $27.3M | $1.7B |
总债务JKHYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $60.0M | — | ||
| Q1 24 | $250.0M | — |
股东权益JKHYRVTY
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.1B | $7.6B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
总资产JKHYRVTY
| Q4 25 | $3.1B | $12.2B | ||
| Q3 25 | $3.0B | $12.1B | ||
| Q2 25 | $3.0B | $12.4B | ||
| Q1 25 | $2.9B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $2.8B | $13.4B |
负债/权益比JKHYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $131.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 21.2% | 21.0% |
| 资本支出强度资本支出/营收 | 3.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.22× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $654.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流JKHYRVTY
| Q4 25 | $152.7M | $182.0M | ||
| Q3 25 | $120.6M | $138.5M | ||
| Q2 25 | $327.1M | $134.3M | ||
| Q1 25 | $107.8M | $128.2M | ||
| Q4 24 | $89.6M | $174.2M | ||
| Q3 24 | $116.9M | $147.9M | ||
| Q2 24 | $231.8M | $158.6M | ||
| Q1 24 | $97.6M | $147.6M |
自由现金流JKHYRVTY
| Q4 25 | $131.4M | $161.8M | ||
| Q3 25 | $111.7M | $120.0M | ||
| Q2 25 | $314.9M | $115.5M | ||
| Q1 25 | $96.1M | $112.2M | ||
| Q4 24 | $73.0M | $149.8M | ||
| Q3 24 | $104.1M | $125.6M | ||
| Q2 24 | $208.0M | $136.6M | ||
| Q1 24 | $87.7M | $129.7M |
自由现金流率JKHYRVTY
| Q4 25 | 21.2% | 21.0% | ||
| Q3 25 | 17.3% | 17.2% | ||
| Q2 25 | 51.2% | 16.0% | ||
| Q1 25 | 16.4% | 16.9% | ||
| Q4 24 | 12.7% | 20.5% | ||
| Q3 24 | 17.3% | 18.4% | ||
| Q2 24 | 37.2% | 19.7% | ||
| Q1 24 | 16.3% | 20.0% |
资本支出强度JKHYRVTY
| Q4 25 | 3.4% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 2.9% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 4.2% | 3.2% | ||
| Q1 24 | 1.8% | 2.7% |
现金转化率JKHYRVTY
| Q4 25 | 1.22× | 1.85× | ||
| Q3 25 | 0.84× | 2.97× | ||
| Q2 25 | 2.56× | 2.49× | ||
| Q1 25 | 0.97× | 3.03× | ||
| Q4 24 | 0.92× | 1.84× | ||
| Q3 24 | 0.98× | 1.57× | ||
| Q2 24 | 2.29× | 2.87× | ||
| Q1 24 | 1.12× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JKHY
| Processing | $273.5M | 44% |
| Private Public Cloud | $202.7M | 33% |
| On Premise Support | $79.0M | 13% |
| Product Deliveryand Service | $64.1M | 10% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
